Table 1.

Criteria for the initiation of therapy in CLL

Criteria for the initiation of therapy in CLL (adapted from iwCLL 2018 guidelines)
Marrow failure: hemoglobin <10 g/dL or platelet count <100 × 109/L
Massive, progressive, or symptomatic splenomegaly
Massive, progressive, or symptomatic lymphadenopathy
Progressive lymphocytosis with ≥50% increase over 2-mo period, or lymphocyte doubling time <6 mo
Autoimmune complications poorly responsive to corticosteroids
Symptomatic extranodal involvement
Disease-related symptoms: weight loss ≥10% over 6 mo, significant fatigue, fevers for 2 or more weeks without infection, night sweats ≥1 mo without infection